Print Page   | Close Window

2014 News Releases

 Previous | Next
August 07, 2014
Teva Comments on Receipt of First Paragraph IV Notice for COPAXONE® 40 mg/mL (glatiramer acetate injection) Formulation
JERUSALEM--(BUSINESS WIRE)--Aug. 7, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE® 40 mg/mL product from Dr. Reddy’s Laboratories, Inc. Teva will continue to vigorously defend its COPAXONE® intellectual property rights against infringement wherever they are challenged. Teva intends to file a lawsuit for patent infringement against Dr. Re  Read More »
July 31, 2014
Teva Reports Second Quarter 2014 Results
Revenues of $5.0 billion, up 2% compared to the second quarter of 2013. Non GAAP operating income of $1.4 billion, an increase of 8%. GAAP operating income of $925 million. Non-GAAP net income of $1.05 billion, an increase of 4%. GAAP net income of $748 million. Non-GAAP diluted EPS of $1.23, an increase of 3%. GAAP diluted EPS of $0.87. Strong cash flow from operations   Read More »
July 30, 2014
All Proposals Approved at Teva's Annual Meeting of Shareholders
JERUSALEM--(BUSINESS WIRE)--Jul. 30, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that all proposals were approved at its Annual General Meeting of Shareholders held earlier today. These proposals included the appointment of directors, the approval of cash bonus objectives and future equity awards for the Chief Executive Officer, directors' and officers' insurance and the appointment of auditors. The voting results are provided  Read More »
July 21, 2014
Teva Completes Acquisition of Labrys: Opens Door to a Strong and Novel Migraine Prevention and Treatment Franchise within its CNS Portfolio
JERUSALEM--(BUSINESS WIRE)--Jul. 21, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the successful completion of the acquisition of Labrys. The acquisition of Labrys brings to Teva LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), which is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine. Teva’s acquisition of LBR-101 complement  Read More »
July 18, 2014
Teva to Report Second Quarter 2014 Financial Results on July 31, 2014
JERUSALEM--(BUSINESS WIRE)--Jul. 18, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will release its second quarter 2014 financial results on Thursday, July 31, 2014 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its second quarter 2014 results and overall business environment. A Question & Answer session will follow this discussion.   Read More »
July 16, 2014
Leading U.S. Proxy Advisory Firm Supports Teva Nominees and Other Shareholders’ Meeting Proposals
JERUSALEM--(BUSINESS WIRE)--Jul. 16, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) reported today that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director (Messrs. Jean-Michel Halfon, Joseph (Yossi) Nitzani, Dan Propper and Ory Slonim) and for each of the other proposals on the agenda for consideration at the Company's upcoming annual genera  Read More »
July 14, 2014
Teva Announces FDA Acceptance of NDA Filing for Investigational Short-Acting Beta-Agonist (SABA) Inhaler (Albuterol MDPI)
First Breath-Actuated Dry-Powder SABA Inhaler to be Accepted by FDA for Review JERUSALEM--(BUSINESS WIRE)--Jul. 14, 2014-- Teva Pharmaceuticals Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bro  Read More »
July 04, 2014
Teva Receives CHMP Positive Opinion for Seasonique® Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries
An Extended Regimen Oral Contraceptive That Provides Quarterly Menses – A New Concept for Women in Europe JERUSALEM--(BUSINESS WIRE)--Jul. 4, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in a referral procedure regarding the authorization of its extended-regimen oral contraceptive, Sea  Read More »
July 03, 2014
Teva Files Citizen Petition with the U.S. Food and Drug Administration (FDA) Regarding the Complexity of COPAXONE® (glatiramer acetate) Following the Agency’s Guidance
Teva includes new gene expression data in its CP, supporting the need for active ingredient sameness of any purported generic version of COPAXONE® JERUSALEM--(BUSINESS WIRE)--Jul. 3, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that the Company has filed a citizen petition (CP) regarding the approvability of purported generic versions of COPAXONE®. Teva submitted this CP according to the FDA’s procedural guidance and  Read More »
June 20, 2014
Teva Reaches Settlement in ProAir® HFA Patent Case
JERUSALEM--(BUSINESS WIRE)--Jun. 20, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that it has reached a settlement with Perrigo Pharmaceutical Co. and Catalent Pharma Solutions LLC with respect to four patents for Teva’s ProAir® HFA (albuterol sulfate) Inhalation Aerosol product. This settlement provides a license to Perrigo and Catalent to sell limited units of Perrigo’s generic version of the product for an initial period beginning  Read More »
June 17, 2014
Teva Reaches Settlements In NUVIGIL® Patent Case
JERUSALEM--(BUSINESS WIRE)--Jun. 17, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that it has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7,132,570 (the “570 patent”) for Teva’s wakefulness product, NUVIGIL® (armodafinil) tablets. These settlements dismiss a pending appeal with the United States Court of Appeals for the Federal Circuit of a trial court decision that found the ‘570 patent to   Read More »
June 12, 2014
Teva Announces U.S. Court of Appeals Upholds Ruling Confirming Invalidity of Baraclude® Patent
JERUSALEM--(BUSINESS WIRE)--Jun. 12, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. Court of Appeals for the Federal Circuit today upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb’s entecavir compound claim of U.S. Patent No. 5,206,244 invalid. Teva’s ANDA for entecavir has received tentative approval from the U.S. Food and Drug Administration (FDA). Teva will finalize th  Read More »
June 09, 2014
FDA Approves Expanded Label for AZILECT® for Treatment Across All Stages of Parkinson’s Disease
JERUSALEM--(BUSINESS WIRE)--Jun. 9, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for AZILECT® (rasagiline tablets) from monotherapy and adjunct to levodopa (LD) to now include adjunct to dopamine agonists (DAs). The new indication reflects that AZILECT® can be used alone or in combination with other Parkinson’s disease (PD) medications. The approval r  Read More »
June 05, 2014
Teva to Present at the Goldman Sachs 35th Annual Global Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--Jun. 5, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Goldman Sachs 35th Annual Global Healthcare Conference. Eyal Desheh, EVP & CFO will present on Tuesday, June 10, 2014 at 2 PM PT. What:   Teva Presentation at the Goldman Sachs 35th Annual Global Healthcare   Read More »
June 03, 2014
Teva to Acquire Labrys Biologics, Inc.: Novel Migraine Prophylaxis Treatment Adds Significant New Dimension to Teva’s Growing Pain Care Franchise
Adds LBR-101, Labrys’ Phase IIb anti-CGRP monoclonal antibody for the prevention of chronic and high frequency episodic migraine. Peak sales potential of $2-3 billion. Teva ideally positioned in the transformational pain market with a wide range of new chemical and biologic entities and NTEs to treat a broad spectrum of pain disorders JERUSALEM & SAN MATEO, Calif.--(BUSINESS WIRE)--Jun. 3, 2014-- Teva Pharmace  Read More »
June 02, 2014
Teva Announces New Organizational Structure and Senior Leadership Changes, Enabling the Global Integration of the Company and Positioning It for Short- and Long-Term Value Creation
APPOINTS SIGURDUR OLAFSSON AS PRESIDENT AND CEO OF NEWLY ESTABLISHED GLOBAL GENERIC MEDICINES GROUP New, fully integrated Global Generic Medicines Group will be responsible for all global commercial activity Newly formed Corporate Development, Strategy and Innovation Group, with broader scope Establishes Global Corporate Marketing Excellence and Communications Group   Read More »
May 30, 2014
Teva Receives Favorable Court Decision Regarding Generic Celebrex® Capsules; Teva Should Receive Sole Exclusivity for Generic Celebrex® Capsules
JERUSALEM--(BUSINESS WIRE)--May 30, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules. On April 17th,Teva entered into a sett  Read More »
May 29, 2014
Teva to Present at the Jefferies 2014 Global Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--May 29, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Jefferies 2014 Global Healthcare Conference. Jon Congleton, SVP & Head of Global CNS will present on Tuesday, June 3, 2014 at 9:00 AM ET. What: Teva Presentation at the Jefferies 2014 Global Healthcare Conference Who: Jon Congleton, SVP & Head of Global CNS, Teva Pharmaceutical Industries L  Read More »
May 27, 2014
Teva Announces Favorable European Patent Office Ruling in COPAXONE® Patent Proceeding
JERUSALEM--(BUSINESS WIRE)--May 27, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party. On September 6, 2012, the three opponents commenced an opposition proceeding against European Patent EP 2 177 528, a patent for COPAXONE® (glatiramer acetate injection) expiring September 9  Read More »
May 23, 2014
Teva Received FDA Approval for QVAR® (beclomethasone dipropionate HFA) with Dose Counter
All Teva Respiratory Brands in the United States Will Soon Be Available With a Dose Counter JERUSALEM--(BUSINESS WIRE)--May 23, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of QVAR® (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients five years of age and older. The dose co  Read More »
May 23, 2014
Teva and Active Biotech to Continue with the Development of Nerventra® (Laquinimod) for Multiple Sclerosis Following Confirmation of CHMP Opinion
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--May 23, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion to recommend against approval for the treatment of relapsing-remitting multiple sclerosis (RRMS) in the European Union (EU) at this time. Both companies remain committed to th  Read More »
May 15, 2014
Teva to Present at the UBS Global Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--May 15, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the UBS Global Healthcare Conference. Eyal Desheh, EVP & CFO will present on Monday, May 19, 2014 at 1:00 PM ET. What: Teva Presentation at the UBS Global Healthcare Conference Who: Eyal Desheh, EVP and CFO, Teva Pharmaceutical Industries Ltd. When: Monday, May 19, 2014 Where: w  Read More »
May 13, 2014
Teva Announces FDA Acceptance of sNDA Filing for Pediatric Indication for QNASL® (Beclomethasone Dipropionate) Nasal Aerosol
First waterless corticosteroid nasal spray to apply for pediatric approval JERUSALEM--(BUSINESS WIRE)--May 13, 2014-- Teva Pharmaceuticals Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental new drug application (sNDA) for a lower dose QNASL® (beclomethasone dipropionate) Nasal Aerosol for the treatment of seasonal and perennial allergic rhinitis in ch  Read More »
May 09, 2014
Teva to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
JERUSALEM--(BUSINESS WIRE)--May 9, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Bank of America Merrill Lynch 2014 Health Care Conference. Eyal Desheh, EVP & CFO will present on Tuesday, May 13, 2014 at 12:00 PM PT. What: Teva Presentation at the Bank of America Merrill Lynch Healthcare Conference Who: Eyal Desheh, EVP and CFO, Teva Pharmaceutical Industries Ltd.   Read More »
May 08, 2014
Teva Announces COPAXONE® Recognized as “Brand of the Year” by Pharmaceutical Executive Magazine
JERUSALEM--(BUSINESS WIRE)--May 8, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that COPAXONE® (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 “Brand of The Year” by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry. “Teva and the COPAXONE® team are honored to be acknowledged by Pharmaceutica  Read More »
May 05, 2014
FDA Approves Teva’s SYNRIBO® (Omacetaxine Mepesuccinate) for Injection for Home Administration
New Labeling will Offer People Living with Chronic Myeloid Leukemia (CML) More Treatment Flexibility JERUSALEM--(BUSINESS WIRE)--May 5, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use. W  Read More »
May 01, 2014
Teva Reports First Quarter 2014 Results
Revenues of $5.0 billion, up 2% compared to the first quarter of 2013. Non-GAAP net income of $1.0 billion, an increase of 8%. GAAP net income of $744 million, an increase of 18%. Non-GAAP diluted EPS of $1.22, an increase of 9%. GAAP diluted EPS of $0.87, an increase of 18%. Successful launch of Copaxone® 40mg/mL in the U.S.; on-track to achieve 30,000 patients on therapy by the end of  Read More »
April 30, 2014
Teva Issues Updated Conference Call Information for First Quarter 2014 Financial Results on May 1, 2014
JERUSALEM--(BUSINESS WIRE)--Apr. 30, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today issued updated dial-in information regarding the conference call to be held on May 1, 2014 at 8:00 a.m. ET to discuss its first quarter 2014 results. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-877-327-2806; Canada 1-800-608-0284 and International +44 (0) 1452 5566  Read More »
April 30, 2014
Teva Reports Positive Results from Pivotal Phase III Study to Evaluate Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Moderate to Severe Chronic Low Back Pain
Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties JERUSALEM--(BUSINESS WIRE)--Apr. 30, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties (CEP-33237). The results s  Read More »
April 30, 2014
Teva Shares New Data on MS Therapies at 66th American Academy of Neurology (AAN) Annual Meeting
Results presented from first head-to-head, open-label, study (GLACIER) comparing the safety and tolerability of new three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg/mL to daily COPAXONE® 20 mg/mL Additional analyses from the GALA study illustrate COPAXONE® 40 mg/mL effect on relapse rates and 12-month MRI metrics Analyses of Phase III laquinimod studies provide additional clin  Read More »
April 29, 2014
Teva Receives European Marketing Authorization for DuoResp Spiromax® for the Treatment of Asthma and COPD
JERUSALEM--(BUSINESS WIRE)--Apr. 29, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the European Commission has granted marketing authorization for DuoResp Spiromax® for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate. DuoResp Spiromax® is a new, multi-dos  Read More »
April 28, 2014
Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer
JERUSALEM & VANCOUVER, British Columbia & BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 28, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostat  Read More »
April 27, 2014
Teva and Takeda Agree to Commercialize Rasagiline for Parkinson’s Disease Treatment in Japan
JERUSALEM & TOKYO--(BUSINESS WIRE)--Apr. 27, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Takeda Pharmaceutical Company Limited (Takeda) have signed an agreement allowing Takeda to commercialize Teva’s innovative treatment for Parkinson’s disease, rasagiline* (active ingredient) in Japan. Developed by Teva, rasagiline tablets are approved in over 40 countries for the treatment of Parkinson’s disease. Teva developed this product   Read More »
April 24, 2014
Pride-HD Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease
– Study initiation represents significant milestone for patients with a disease with limited effective treatment options – JERUSALEM--(BUSINESS WIRE)--Apr. 24, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today enrollment of the first patient in The Pride-HD study, a phase II, randomized, double-blind, placebo-controlled global study designed to evaluate the impact of pridopidine, an investigational medication, on motor im  Read More »
April 19, 2014
Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE® Patent Due to the Potential for the Company to Recover Patent Infringement Damages
The Chief Justice Found That Teva Had Demonstrated “a Fair Prospect of Success on the Merits” JERUSALEM--(BUSINESS WIRE)--Apr. 19, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that while the Chief Justice of the United States found that Teva had demonstrated “a fair prospect of success on the merits” in its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S  Read More »
April 17, 2014
Teva Settles Patent Litigation with Pfizer on Celebrex®
JERUSALEM--(BUSINESS WIRE)--Apr. 17, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva’s generic version of Celebrex® (celecoxib) 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has rec  Read More »
April 15, 2014
Teva Announces Launch of Generic Lunesta® Tablets in the United States
JERUSALEM--(BUSINESS WIRE)--Apr. 15, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Lunesta® (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States. Lunesta® Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of approximately $852 million in the United States, according to IMS data as of December 2013. About Teva Teva Pharmaceutical Indus  Read More »
April 08, 2014
Teva Announces First Approval and Launch of Generic Lovaza® Capsules in the United States
JERUSALEM--(BUSINESS WIRE)--Apr. 8, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States. Teva believes it is first-to-file and thus far is the only Company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza® Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $  Read More »
March 31, 2014
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE® Patent
JERUSALEM--(BUSINESS WIRE)--Mar. 31, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company’s COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the “’808 patent”). The 808 patent expires on September 1, 2015 and claims a process for manufacturing  Read More »
March 20, 2014
Teva to Report First Quarter 2014 Financial Results on May 1, 2014
JERUSALEM--(BUSINESS WIRE)--Mar. 20, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2014 financial results on Thursday, May 1, 2014 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2014 results and overall business environment. A Question & Answer session will follow this discussion.   Read More »
March 13, 2014
Teva Hosts UK and Israeli Prime Ministers at UK-Israel Innovation Event – Announce Collaboration on New National Clinical Drug Development Initiative and Dementia Research
Teva to collaborate on new UK Government-led clinical drug development initiative The initiative creates a single point of entry into the UK health system reducing complexity and increasing speed, efficiency of running drug development programs Teva plans to invest approximately $20 million in clinical development in the UK and up to an additional $1 million for basic research into dementia – one of th  Read More »
March 10, 2014
Teva Pharmaceuticals and Volunteers in Medicine Partner to Expand Access to Healthcare in the U.S.
NORTH WALES, Pa. & BURLINGTON, Vt.--(BUSINESS WIRE)--Mar. 10, 2014-- Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Volunteers in Medicine (VIM), a national nonprofit organization dedicated to helping communities provide free primary healthcare clinics for families and individuals, today announced their 2014 National Partnership to make healthcare services more readily available to the uninsured.   Read More »
March 07, 2014
Teva Announces Launch of Generic Xeloda® Tablets 150 MG and 500 MG in the United States
JERUSALEM--(BUSINESS WIRE)--Mar. 7, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Xeloda® (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda® is marketed by Genentech in the United States. Teva was the first to receive approval on its ANDA from the U.S. Food and Drug Administration on September 16, 2013 and is launching today per a settlement agreement. Xeloda  Read More »
March 04, 2014
Teva Announces Approval of Generic Evista® Tablets 60 mg in the United States
JERUSALEM--(BUSINESS WIRE)--Mar. 4, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval of the generic equivalent to Evista® (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Teva will begin shipping the product within the next 30 days. Evista® 60 mg Tablets marketed by Eli Lilly and Company, had annual sales of approximate  Read More »
March 03, 2014
Teva Launches ADASUVE® in U.S.
The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults JERUSALEM--(BUSINESS WIRE)--Mar. 3, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today the commercial launch of ADASUVE® (loxapine) inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disor  Read More »
February 28, 2014
Teva to Present at the Cowen & Company 34th Annual Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--Feb. 28, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Cowen & Company 34th Annual Healthcare Conference in Boston, MA. Eyal Desheh, EVP & CFO will present on Tuesday, March 4, 2014 at 11:20 AM EST What:   Teva Presentation at the Cowen & Company 34th   Read More »
February 24, 2014
Teva Files 2013 Annual Report on Form 20-F
JERUSALEM--(BUSINESS WIRE)--Feb. 24, 2014-- In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (“Teva”) announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, securi  Read More »
February 24, 2014
Teva to Present at the Citi 2014 Global Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--Feb. 24, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Citi 2014 Global Healthcare Conference in New York, NY. Dr. Michael Hayden, President of Global R&D & CSO will present on Wednesday, February 26, 2014 at 1:50 PM EST   What:   Read More »
February 21, 2014
Teva Completes Tender Offer for NuPathe Inc. Shares
Merger Expected to Close Today 80% of Shares Tendered JERUSALEM--(BUSINESS WIRE)--Feb. 21, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (“Teva”) today announced the successful completion of the tender offer (the “Offer”) by Train Merger Sub, Inc. (“Merger Sub”), a wholly-owned subsidiary of Teva, for all of the outstanding shares of common stock of NuPathe Inc. (Nasdaq:PATH) (“NuPathe”) at a price of $3.65 per share in cash a  Read More »
February 21, 2014
Teva Receives CHMP Positive Opinion for DuoResp® Spiromax® for the Treatment of Patients Diagnosed with Asthma and COPD in Europe
Innovative new inhaler for asthma and COPD patients JERUSALEM--(BUSINESS WIRE)--Feb. 21, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for DuoResp® Spiromax® (budesonide & formoterol fumarate dihydrate) inhalation powder for the treatment of patients with asthma and chronic obstructive pulmonary disease  Read More »
February 13, 2014
Teva Announces Full FDA Approval of SYNRIBO® (Omacetaxine Mepesuccinate) for Injection
24-Month FDA Post Marketing Commitment Completed JERUSALEM--(BUSINESS WIRE)--Feb. 13, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of SYNRIBO® (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requir  Read More »
February 06, 2014
Teva Reports Fourth Quarter and Full Year 2013 Results
Fourth Quarter 2013 Net Revenues of $5.4 Billion and Full Year Net Revenues of $20.3 Billion Fourth Quarter 2013 Non-GAAP EPS of $1.42, GAAP diluted EPS of $0.45; Full Year Non-GAAP EPS of $5.01, GAAP diluted EPS of $1.49 COPAXONE® Remains the Leading Global MS Therapy with Record Annual Revenues of $4.3 Billion Robust Cash Flow Supports Return to Shareholders, Capital Expenditures, Deb  Read More »
January 28, 2014
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE® (glatiramer acetate injection) 40mg/mL
New Formulation of COPAXONE® Offers Patients and Their Physicians Ability to Dose Less Frequently JERUSALEM--(BUSINESS WIRE)--Jan. 28, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental new drug application (sNDA) for three-times-a-week COPAXONE® 40mg/mL, a new dose of COPAXONE®. This new formulation will allow for a less frequent dosi  Read More »
January 24, 2014
Teva and Active Biotech Remain Committed to the Development of NERVENTRA® (laquinimod) for Multiple Sclerosis Following the Negative Opinion from the EMA’s CHMP
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Jan. 24, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for H  Read More »
January 21, 2014
Teva Expands CNS Specialty Business with Acquisition of NuPathe
JERUSALEM--(BUSINESS WIRE)--Jan. 21, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that it has entered into a definitive agreement under which Teva will acquire NuPathe Inc. (Nasdaq:PATH) for $3.65 per share in cash, or approximately $144 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe’s migrai  Read More »
January 13, 2014
Data Demonstrates Key Genes Respond Differently to COPAXONE® (glatiramer acetate injection) Versus a Purported Generic Glatiramer Acetate
Multiple genes associated with potential therapeutic effects expressed differently: Gene expression analysis provides insight into variability JERUSALEM--(BUSINESS WIRE)--Jan. 13, 2014-- Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) today announced the publication of data that demonstrates significant differences in biological and immunological effects between COPAXONE® (glatiramer acetate, GA) and a purported generic glatiramer acetate   Read More »
January 09, 2014
Teva to Present at the 32nd Annual J.P. Morgan Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--Jan. 9, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Acting President & CEO will present on Tuesday, January 14, 2014 at 10:30 AM PT.   What:     Read More »
January 09, 2014
Teva Names Erez Vigodman as President and CEO
Brings global leadership and business transformation experience Provides strong strategic expertise across multiple industries and deep insight into global market dynamics JERUSALEM--(BUSINESS WIRE)--Jan. 9, 2014-- Teva Pharmaceutical Industries Ltd (NYSE:TEVA) today announced that Erez Vigodman, 54, has been appointed President and Chief Executive Officer, effective February 11, 2014. Mr. Vigodman will succeed acting Pres  Read More »
January 03, 2014
Teva Announces Launch of Authorized Generic of Detrol®
JERUSALEM--(BUSINESS WIRE)--Jan. 3, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of the Authorized Generic of Detrol®* LA (tolterodine tartrate extended-release capsules) 2 mg and 4 mg in the U.S. market. Detrol® LA had annual sales of approximately $571.5 million in the U.S., according to IMS data as of September 30, 2013. *Detrol® is a registered trademark of Pfizer Enterprises Sarl. About Te  Read More »
 Previous | Next